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Abstract
Background: Prisoners represent a vulnerable population for blood-borne and sexually transmitted infections which
can potentially lead to liver fibrosis and ultimately cirrhosis. However, little is known about the prevalence of liver
fibrosis and associated risk factors among inmates in sub-Saharan Africa.
Methods: Screening of liver fibrosis was undertaken in a randomly selected sample of male inmates incarcerated in
Lome, Togo and in Dakar, Senegal using transient elastography. A liver stiffness measurement ≥9.5 KPa was retained to
define the presence of a severe liver fibrosis. All included inmates were also screened for HIV, Hepatitis B Virus (HBV)
and Hepatitis C Virus (HCV) infection. Substances abuse including alcohol, tobacco and cannabis use were assessed
during face-to-face interviews. Odds Ratio (OR) estimates were computed with their 95 % Confidence Interval (CI) to
identify factors associated with severe liver fibrosis.
Results: Overall, 680 inmates were included with a median age of 30 years [interquartile range: 24–35]. The prevalence
of severe fibrosis was 3.1 % (4.9 % in Lome and 1.2 % in Dakar). Infections with HIV, HBV and HCV were identified in 2.
6 %, 12.5 % and 0.5 % of inmates, respectively. Factors associated with a severe liver fibrosis were HIV infection
(OR = 7.6; CI 1.8–32.1), HBV infection (OR = 4.8; CI 1.8–12.8), HCV infection (OR = 52.6; CI 4.1–673.8), use of traditional
medicines (OR = 3.7; CI 1.4–10.1) and being incarcerated in Lome (OR = 3.3; CI 1.1–9.8) compared to Dakar.
Conclusions: HIV infection and viral hepatitis infections were identified as important and independent determinants of
severe liver fibrosis. While access to active antiviral therapies against HIV and viral hepatitis expands in Africa, adapted
strategies for the monitoring of liver disease need to be explored, especially in vulnerable populations such as inmates.
Keywords: Liver fibrosis, HIV, Hepatitis B, Hepatitis C, Africa
Background
Worldwide, liver cirrhosis, the final stage of liver fibrosis,
is a significant public health problem. Indeed, deaths at-
tributable to liver cirrhosis increased from around 676,000
in 1980 to over 1 million in 2010 representing about 2 %
of the overall number of deaths [1]. However, the paucity
of data on the specific causes of death in sub-Saharan
Africa severely limits a reliable assessment of the true
burden of disease in this part of the world [2].
Diagnosis of liver fibrosis classically relies on histology
through liver biopsy. However, this invasive method has
many limitations including iatrogenic effects, high cost
and the need for adequately trained pathologists, chal-
lenging its use in low-income countries. Recently, several
non-invasive liver fibrosis measurement methods have
been developed to overcome some of the challenges re-
lated to liver biopsy. Of these, transient elastography
(Fibroscan®, Echosens, France) based on liver stiffness
measurement (LSM), has proven to be accurate in a wide
spectrum of liver diseases including hepatitis C virus
(HCV) and hepatitis B virus (HBV) infections [3–6]. The
availability of these simple diagnostic tools as well as treat-
ment options for many of these etiologic conditions makes
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the assessment of liver fibrosis particularly relevant, es-
pecially in populations presenting a high risk of liver
disease [7].
Prisons are known to be a high-risk environment for
addictive behaviors as well as blood-borne and sexually
transmitted infections which can lead to liver damage [8].
Several factors contribute to this increased risk of commu-
nicable diseases including promiscuity, risk behaviors as
well as poor access to diagnostic and preventive measures.
Indeed, infection with Human Immunodeficiency Virus
(HIV) as well as chronic HBV and HCV infections are
common in these populations [9, 10]. In sub-Saharan
Africa where few data on the health of prisoners are
available, studies have mainly focused on the prevalence
of HIV infection and tuberculosis [11–15]. However, lit-
tle is known about the prevalence of viral hepatitis in
these settings. In West Africa, two studies conducted in
Nigeria and Ghana a few years ago showed a particularly
high prevalence of viral hepatitis in prisons [16–18].
In a context of expanding access to efficient antiviral
therapies for HIV infection and viral hepatitis in sub-
Saharan Africa, there is a need to document the level
liver damage in vulnerable populations such as inmates.
Our aim was to investigate liver fibrosis and associated
factors among inmates incarcerated in West Africa.
Methods
Study population and data collection
Screening of liver fibrosis was undertaken in a randomly
selected sample of inmates incarcerated in September -
October 2013 in the state prison of Lome (Togo) and in
April - May 2014 in the state prison of Dakar (Senegal).
For logistics reasons and acceptability, we conducted a
cluster sampling approach using prison cells as the stat-
istical units. Prison cells were mapped and ranked according
to their size (number of prisoners currently incarcerated in
each cell during the study period). A randomly selected
group of cells were then selected by applying sampling inter-
val to this list in order to identify a study sample of approxi-
mately 350 inmates in each participating state prison. All
the inmates from a selected cell were invited to participate.
Only adults men (≥18 years) were included. All included in-
mates were informed about implications related to their
study participation and provided their signed informed
consent. All participants accessed to a baseline medical
consultation and received counseling with regards to
their serological status if positive for HIV and/or hepa-
titis viruses. The national programs for HIV/AIDS in
Senegal and Togo currently ensure a universal access to
care and treatment with highly active antiretroviral for
eligible patients. Both prisons have a medical unit that
ensures access to HIV care supported by the national
HIV/AIDS program. All participants with a positive HIV
test were notified to the national HIV program of their
respective country and accessed to HIV care and treat-
ment, if eligible. As access to treatment for hepatitis B or
C is currently not free of charge, we were not able to guar-
antee treatments and long term follow-up of inmates who
had a positive hepatitis B or C screening test. Prison doc-
tors were in charge to reefer participants with a positive
HBV or HCV test to infectious disease units in teaching
hospitals in Lome (Silvanus Olympio university hospital)
and Dakar (Fann university hospital) for a free baseline
consultation once all biological tests including viral loads
were available.
Standardized questionnaires were administered in French
or local language by nurses from the prison medical staff
through face-to-face interviews. Socio-demographic data
(age, number and duration of incarcerations) as well as be-
havioral information including drug use (alcohol, tobacco,
cannabis, cocaine/crack and heroin) were reported. Alcohol
use during the last 12 months was scored with the alcohol
use disorder identification test (AUDIT). This test devel-
oped by the World Health Organization (WHO) has been
specifically designed to screen for individuals experien-
cing active alcohol abuse and/or dependence. The AUDIT
includes 10 questions, each of them scored from 0 to 4
points for a maximum score of 40 points. According to
their AUDIT score patients were classified as abstinent
(AUDIT = 0), present alcohol users or hazardous drinkers
using a standard cut-off of ≥8 points [19]. Self-report of
tobacco, cannabis, cocaine/crack and heroin use allowed
the classification of the respondents as nonusers, past
users or current users. Information on present or past his-
tory of injection drug use was also collected. The ingestion
of herbs through traditional medicine was reported based
on participants declaration categorized as nonusers, occa-
sional users or frequent users. Height and weight were
systematically measured and reported on the case report
form in order to compute the body mass index (BMI).
Laboratory measurements
Viral hepatitis infections were assessed using rapid diagnos-
tic tests: Determine® (Alere, Waltham, MA, United States
of America (USA)) for HBs antigen and Oraquick®
(Orasure, Bethlehem, PA, USA) for anti-HCV antibodies
as these tests have shown relatively good diagnostic accur-
acy [20–22]. Infection with HIV was first assessed with
the rapid diagnostic test Determine® (Alere, Waltham,
MA, USA) and confirmed with additional tests according
to national recommended algorithms in Senegal and
Togo. Alanine aminotransferase (ALT) and Aspartate
aminotransferase (AST) were also measured for partici-
pants who were positive for HBV and/or HCV rapid
diagnostic tests. Results of ALT/AST were reported in
international units (IU) per L. For ALT a threshold of
30 IU/L was considered to define ALT elevation [23].
Those who were positive for the HBV test underwent a
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viral load quantification by polymerase chain reaction
using the COBAS(R) AmpliPrep/COBAS(R) TaqMan(R)
v2.0 (Roche®) kit in Senegal and the ABBOTT M2000RT
(Abbot®) kit in Togo. Inmates from Lome and Dakar with
a positive HCV test underwent viral load quantification by
polymerase chain reaction using the Roche® kit centralized
in Dakar. Results were reported in international units (IU)
per ml. For HBV, a threshold of 2 000 IU/ml was consid-
ered for clinically significant viral load replication and a
threshold of 20 000 IU/ml for high viral load replication
as suggested in the recent European guidelines for the
management of chronic HBV infection [24]. All laboratory
tests were performed according to the manufacturer’s
specifications.
Transient elastography
All participants were assessed for liver fibrosis using a
portable transient elastography device (Fibroscan 402®,
Echosens, Paris) with an M probe. A single device was
made available for a two-month period in each partici-
pating state prison. A maximum of two operators were
specifically trained to perform the examination at each
site. All operators followed the online formal training
and certification from the manufacturer. Prior to the study
inclusions, they all went through a practical training ses-
sion supervised by experienced physicians. To be consid-
ered reliable, the examination must include at least 10
measurements with an interquartile range (IQR) equal or
below 30 % of the median value (IQR/LSM ≤30 %) [25].
Participants for who these criteria were not achieved after
several attempts were excluded from the present analysis.
The median value of ten successive validated LSM was
used to represent liver stiffness.
Statistical analysis
A cutoff value of LSM ≥9.5 kPa was used to define the
presence of severe liver fibrosis. This threshold was re-
ported in a recent meta-analysis as the median optimal
cut-off to define a severe liver fibrosis that approximates
a ≥ F3 stage using the METAVIR score among popula-
tions presenting with various etiological factors for liver
fibrosis. A cut-off value of ≥14.4 KPa was used to define
the presence of cirrhosis [26].
Pearson’s χ2 test or Fisher’s exact test were used to
compare categorical variables according to the presence
of a severe liver fibrosis or to participating state prisons.
Kruskall-Wallis test was used for comparisons between
continuous variables. A corrected logistic regression using
the Firth’s penalized likelihood method was used to assess
factors associated with severe liver fibrosis [27]. A step-
wise descending procedure was used to select the final
multivariable model. All potential confounding variables
were included in the initial model. The Akaike informa-
tion criterion was used to assess the goodness of fit of the
model. A low value of this criterion is associated with a
better prediction of the model. Proportions and Odds
Ratio (OR) estimates were reported with their 95 %
Confidence Interval (95 % CI). Statistical analyses were
computed using SAS software 9.2 (SAS Institute Inc.
NC. USA).
Ethics statement
The present study is in compliance with the Helsinki
Declaration and was approved by the national ethic
committees of Senegal (‘Comite National d’Ethique pour
la Recherche en Sante au Senegal’, approval number:
3226/MJ/DAP/SMS) and Togo (‘Comite de Bioethique
pour la Recherche en Sante du Togo’, approval number:
004/2013).
Results
Initially, 787 participants were approached to participate
and 78 were excluded for the following reasons: refusals
(n = 48), transferred to another prison (n = 10) or liber-
ated (n = 20). Of the 709 participants screened for HIV,
HBV, HCV and liver fibrosis, 29 (4.1 %) were subse-
quently excluded from the final analysis for the following
reasons: unreliable LSM (n = 20), indeterminate/unknown
HBV, HCV or HIV status (n = 4) and age < 18 years (n = 5).
A total of 680 inmates were finally included in the analysis
in Lome (n = 347) and Dakar (n = 333). Their median age
was 30 years [interquartile range (IQR): 24–35] and their
median time of incarceration was 8 months [IQR 2–27].
Of these inmates currently incarcerated, 125 (18.4 %) had a
past history of previous incarceration. Hazardous drinking
and current tobacco use were reported in 58 (8.6 %) and
315 (46.4 %) inmates, respectively. A current or past use of
cannabis, cocaine/crack and intravenous use of heroin was
reported in 230 (33.8 %), seven (1.0 %) and four (0.6 %)
inmates, respectively.
The prevalence of severe fibrosis was 3.1 % [95 % CI
1.8–4.4] (Table 1). A marked difference in severe liver fi-
brosis was observed between inmates in Lome and Dakar
with prevalence of 4.9 % [95 % CI 2.6–7.2] and 1.2 %
[95 % CI 0.3–2.4], respectively (p < 0.01). No cases of
cirrhosis were reported. Overall, HIV infection was
identified in 2.6 % [95 % CI 1.4–3.8] of inmates, 3.5 %
[95 % CI 1.5–5.4] in Lome and 1.8 % [95 % CI 0.4–3.2]
in Dakar (Table 2). A past history of HIV testing prior
to the study was reported by 213 (31.3 %) participants.
Of the 18 inmates identified as HIV-infected, only one
was aware of his HIV infection and was already on anti-
retroviral therapy.
Infection with HBV was documented in 85 inmates
(12.5 % [95 CI 10.0–15.0]) with no significant difference
between inmates in Lome (10.9 %) and Dakar (14.1 %)
(p = 0.21). Of the 85 HBV-infected inmates, seven (8.2 %)
had a severe fibrosis. One patient was co-infected with both
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HIV and HBV. The presence of an ALT value >30 IU/ml
was reported in 29 (35.8 %) HBV-positive patients, with no
significant difference between participants with severe fi-
brosis (42.9 %) or without (35.1 %) (P = 0.89). The quantifi-
cation of HBV viral load was performed in 69 (81.2 %) of
these individuals. The remaining 16 inmates could not be
assessed for HBV viral load for various reasons (refusals,
released before the time of blood collection). Signifi-
cant (>2 000 IU/ml) and high HBV replication levels
(>20 000 IU/ml) were reported in 33 (47.8 %) and 26
(37.7 %) inmates assessed for HBV viral load, respectively.
Among the seven patients with severe fibrosis, six (85.7 %)
presented with a high HBV replication level or a high ALT
value compared to 31 (50 %) in the remaining 62 patients
without severe fibrosis (p = 0.07) (Fig. 1).
HCV infection was documented in three participants
providing an estimated prevalence of 0.5 % [95 % CI
0.1–0.9]. Only one out of the three positive tests was
Table 1 Main characteristics of inmates according to their place of incarceration (n = 680)
State prison of Dakar (Senegal) State prison of Lome (Togo) p Total
(n = 333) (n = 347) (n = 680)
Age (median, [IQR]), years 31 [26–36] 28 [23–33] <0.0001 30 [24–35]
Duration of incarceration (median, [IQR]), months 12 [1–34] 8 [3–18] 0.1 8 [2–27]
Past history of incarceration, n (%) <0.0001
No 247 (74.2) 308 (88.8) 555 (81.6)
Yes 86 (25.8) 39 (11.2) 125 (18.4)
Tobacco, n (%) <0.0001
No use 83 (24.7) 189 (54.5) 272 (39.9)
Past use 37 (11.1) 56 (16.1) 93 (13.7)
Present use 213 (64.2) 102 (29.4) 315 (46.4)
Cannabis, n (%) <0.0001
No use 180 (54.1) 270 (77.8) 450 (66.2)
Past use 128 (38.4) 51 (14.7) 179 (26.3)
Present use 25 (7.5) 26 (7.5) 51 (7.5)
Alcohol usea, n (%) <0.0001
No 305 (91.6) 222 (63.7) 526 (77.4)
Current drinking 10 (3.0) 86 (24.8) 96 (14.1)
Hazardous drinking 18 (5.4) 40 (11.5) 58 (8.5)
Cocaine/crack, n (%) 0.43
No use 329 (98.8) 344 (99.1) 673 (99.0)
Present/Past use 4 (1.2) 3 (0.9) 7 (1.0)
Heroinb, n (%) 0.97
No use 331 (99.4) 345 (99.4) 676 (99.4)
Present/Past use 2 (0.6) 2 (0.6) 4 (0.6)
HIV testc, n (%) 0.18
Negative 327 (98.2) 335 (96.5) 662 (97.4)
Positive 6 (1.8) 12 (3.5) 18 (2.6)
HBV testc, n (%) 0.21
Negative 286 (85.9) 309 (89.0) 595 (87.5)
Positive 47 (14.1) 38 (10.9) 85 (12.5)
HCV testd, n (%) 0.54
Negative 331 (99.4) 346 (99.7) 677 (99.5)
Positive 2 (0.6) 1 (0.3) 3 (0.5)
aReported alcohol use during the last 12 month assessed with the Alcohol Use Disorders Identification Test (AUDIT)
bIntravenous drug use
cRapid diagnostic test: Determine® (Alere, Waltham, MA, USA)
dRapid diagnostic test: Oraquick® (Orasure, Bethlehem, PA, USA)
Abbreviations: HIV Human Immunodeficiency Virus, HBV Hepatitis B Virus, HCV: Hepatitis C virus, IQR: Inter Quartile Range
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confirmed by viral load quantification with a value of
5.91 log (IU/ml). None of the three prisoners positively
screened for HCV infection reported intravenous drug
use.
In a multivariate analysis, factors associated with a se-
vere liver fibrosis were HIV infection (OR = 7.6; 95 % CI
1.8–32.1), HBV infection (OR = 4.8; 95 % CI 1.8–12.8),
HCV infection (OR = 52.6; 95 % CI 4.1–673.8), use of
traditional medicines (OR = 3.7; 95 % CI 1.4–10.1) and
incarceration in Lome (OR = 3.3; 95 % CI 1.1–9.8)
(reference: civil prison of Dakar) (Table 3). No signifi-
cant differences in addictive behaviors according to
the presence of severe liver fibrosis were noted includ-
ing alcohol use (OR = 1.0; 95 % CI 0.4–3.0) versus no
use or present/past cannabis use (OR = 1.0; 95 % CI
0.4–2.5) versus no use. None of the four inmates
Table 2 Main characteristics of inmates according to the presence of a severe liver fibrosis assessed by transient elastography
(n = 680), 2013–2014
Median transient elastography
measures
<9.5 KPa ≥9.5 KPa p Total
No severe liver fibrosis Severe liver fibrosis
(n = 659) (n = 21) (n = 680)
Age (median, [IQR]) 30 [24–35] 31 [28–35] 0.46 30 [24–35]
State prison, n (%) <0.01
Dakar (Senegal) 329 (49.9) 4 (19.0) 333 (49.0)
Lome (Togo) 328 (50.1) 17 (81.0) 347 (51.0)
Tobacco, n (%) 0.98
No use 264 (40.0) 8 (38.1) 272 (39.9)
Past use 90 (13.7) 3 (14.3) 93 (13.7)
Present use 305 (46.3) 10 (47.6) 315 (46.4)
Cannabis, n (%) 0.41
No use 436 (66.1) 14 (66.7) 450 (66.2)
Past use 175 (26.6) 4 (19.0) 179 (26.3)
Present use 48 (7.3) 3 (14.3) 51 (7.5)
Alcohol usea, n (%) 0.19
No 510 (77.4) 16 (76.2) 526 (77.4)
Current drinking 91 (13.8) 5 (23.8) 96 (14.1)
Hazardous drinking 58 (8.8) 0 (0.0) 58 (8.5)
Herbal medicineb, n (%) <0.01
No use 194 (29.4) 4 (19.0) 198 (29.1)
Occasional use 409 (62.1) 10 (47.6) 419 (61.6)
Frequent use 56 (8.5) 7 (30.4) 63 (9.3)
HIV testc, n (%) 0.01
Negative 644 (97.7) 18 (85.7) 662 (97.4)
Positive 15 (2.3) 3 (14.3) 18 (2.6)
HBV testc, n (%) <0.01
Negative 581 (88.2) 14 (66.7) 595 (87.5)
Positive 78 (11.8) 7 (33.3) 85 (12.5)
HCV testd, n (%) <0.01
Negative 657 (99.7) 20 (95.2) 677 (99.5)
Positive 2 (0.3) 1 (4.8) 3 (0.5)
Body Mass Indexe 22.8 [21.0–25.3] 22.4 `[19.8–24.4] 0.38 22.8 [21.0–25.3]
aReported alcohol use during the last 12 month assessed with the Alcohol Use Disorders Identification Test (AUDIT)
bReported use of traditional medicine with ingested herbs
cRapid diagnostic test: Determine® (Alere, Waltham, MA, USA)
dRapid diagnostic test: Oraquick® (Orasure, Bethlehem, PA, USA)
e47.4 % of missing values
Abbreviations: HIV Human Immunodeficiency Virus, HBV Hepatitis B Virus, HCV Hepatitis C virus, IQR Inter Quartile Range
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reporting intravenous drus use presented with a severe
liver fibrosis.
Discussion
The prevalence of HIV infection was relatively high in
inmates currently incarcerated in the state prisons of
Lome and Dakar and independently associated with liver
fibrosis. Indeed, reported HIV prevalence from these
state prisons, were two to four times higher than the re-
spective prevalence of HIV infection in the general adult
population of Togo and Senegal [28]. Although sparse
data exist on HIV prevalence in prisoners in these coun-
tries, our results are in accordance to a previous report
from Togo where HIV prevalence in incarcerated men
was estimated at 4.0 % [29]. Together with the fact that
only one out of the 18 patients identified as HIV-infected
was aware of its status; these results emphasize the need
to promote HIV screening and access to care in prisons in
sub-Saharan Africa.
The independent association between HIV infection
and liver fibrosis has already been reported in sub-Saharan
Africa. Stabinski et al conducted a case-control study on
the association between HIV infection and severe liver
fibrosis using the same non-invasive approach in Uganda
[30]. Adjusted for various risk factors including HBV
infection, HIV infection was significantly associated
with liver fibrosis (OR = 1.5 [95 % CI 1.1–2.1]). Poten-
tial reasons for this association are numerous; various
unmeasured tropical hepatotoxic infectious agents such
as schistosomiasis may have synergistically interacted
with HIV infection in the development of liver fibrosis.
Our population of HIV-infected patients was mostly
unaware of their HIV status and potentially had uncon-
trolled HIV replication. The direct toxicity of HIV on
liver cells has been reported in previous studies through
several mechanisms including, stellate cells activation,
apoptotic effect on hepatocytes and immune activation
[31–34]. A recent cohort study exploring factors associ-
ated with the occurrence of liver fibrosis in more than
14 000 HIV-infected persons identified HIV viral load
as a main and independent determinant of progression
to liver fibrosis [35]. Therefore, the high prevalence of
liver fibrosis among HIV-infected persons reported in
Uganda, Nigeria and in our study using the same meth-
odological approach might be partly mediated by the
direct toxicity of HIV itself [36]. Further etiologic and
prospective studies will need to explore the exact mecha-
nisms leading to liver fibrosis in HIV-infected persons
without HBV or HCV in sub-Saharan Africa.
Both HBV and HCV infections were independently
associated with severe liver fibrosis. The high prevalence
of HBV infection was consistent with the prevalence of
HBs antigen positivity in the general population in
West Africa [37]. In addition, we provide here one of
the rare reports of the impact of HBV infection on the
liver. Almost 10 % of inmates positively screened for
HBV were diagnosed with severe liver fibrosis making
them potentially eligible to antiviral treatment regard-
less of other biomarkers. More than one-third of HBV-
infected inmates harbored a high HBV DNA replication
Fig. 1 Proportion of participants with high hepatitis B Virus replication (≥20 000 IU/ml) or high ALT level (>30 IU/l) in HBV-infected inmates
according to the presence of a severe liver fibrosis (n = 69). Lome (Togo) and Dakar (Senegal), 2013–2014. * Median liver stiffness measure.
† 69 HBVviral load available out of the 85 HBV-infected participants
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(>20 000 UI/ml), a well-known negative prognostic fac-
tor in HBV infection, regardless of the presence or ab-
sence of severe liver fibrosis. In a context of limited
access to antiviral treatment for HBV-infected persons
living in sub-Saharan Africa, the availability of reliable
and appropriate tools for the assessment of liver fibrosis is
of paramount importance to identify and prioritize pa-
tients in need for treatment.
A low prevalence of HCV infection was observed in
our study sample, even lower than the available regional
estimates [2.8 % (95%CI 2.4–3.3)] from West Africa [38].
However, this previous estimates from West Africa re-
lied on a limited number of studies with selected popu-
lations and no information was available for several
countries including Togo [39]. Prevalence studies among
blood donors in Senegal reported prevalence of positive
HCV serology of 0.7 % and 0.5 % [40, 41]. Therefore, the
prevalence of HCV infection in West Africa is probably
not homogenous according to countries and deserves
more well conducted representative prevalence studies.
As HCV prevalence increases with age, the fact that half
of our population was under 30 might partly explain this
low HCV prevalence. However, previous surveys among
incarcerated people in Ghana and Nigeria have found
particularly high HCV prevalence (over 10 %) [17, 18].
The spread of the HCV epidemic is mainly driven by
blood exposure including intravenous drug use and un-
safe medical practices through none adapted or inexistent
sterilization process. In light of the marginal reporting of
injected drug-use in our study sample, HCV was unlikely
to have spread through this mode. Accurate estimates of
HCV infection are currently limited by the availability of
reliable serological assays and would benefit from larger
standardized prevalence studies. Indeed, previous reports
have highlighted the high rates of false positive results
using the classical immunoassay techniques for the
screening of HCV infection [42, 43]. Thus, the good
sensitivity and specificity of the Oraquick® test used in
our study might partly explain the discrepancy between
our findings and previous reports on HCV prevalence
Table 3 Factors associated with a severe liver fibrosis defined as a median liver stiffness measure ≥9.5 KPa in inmates of state
prisons in Dakar and Lomé, West Africa (n = 680), 2013–2014
Univariate analysis Multivariable analysis
n/N OR (95 % CI) p OR (95 % CI) p
Age 0.81
≤35 years 17/527 1
>35 years 4/153 0.9 (0.3–2.5)
State prison 0.01 0.03
Dakar, Senegal 4/333 1 1
Lome, Togo 17/347 3.9 (1.4–11.1) 3.3 (1.1–9.8)
Alcohol use 0.80
No use 16/526 1
Current/Hazardous drinkinga 5/154 1.1 (0.4–3.0)
HIV testb <0.01 0.01
Negative 18/662 1 1
Positive 3/18 7.9 (2.2–28.2) 7.6 (1.8–32.1)
HBV testb <0.01 <0.01
Negative 14/595 1 1
Positive 7/85 3.8 (1.5–9.6) 4.8 (1.8–12.8)
HCV testc 0.01 <0.01
Negative 20/677 1 1
Positive 1/3 19.8(1.2–207.5) 52.6 (4.1–673.8)
Herbal medicined <0.00 0.01
No or occasional use 14/617 1 1 1
Frequent use 7/63 5.5 (2.2–14.0) 3.7 (1.4–10.1)
n/N: number of inmates with sever fibrosis/total number of inmates for a specific category
aReported alcohol use during the last 12 month measured with AUDIT questionnaire
bRapid diagnostic test: Determine® (Alere, Waltham, MA, USA)
cRapid diagnostic test: Oraquick® (Orasure, Bethlehem, PA, USA)
dReported use of traditional medicine with ingested herbs
Abbreviations: HIV Human Immunodeficiency Syndrome, HBV Hepatitis B Virus, HCV Hepatitis C Virus, OR Odd Ratio, CI Confidence Interval
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in West Africa [20, 21]. While new potent but expen-
sive cure strategies are emerging for HCV infection, a
better knowledge of the epidemiology of HCV infection
is urgently needed in low-income countries.
Use of herbal medicines was not uncommon in our
study population and was associated with severe liver fi-
brosis. This finding confirmed the result from a report
in Uganda where an in-depth assessment of herbs con-
sumed showed that the Asteraceae family was associated
with liver fibrosis [44]. There is a need to explore the
types of herbs in relation to liver fibrosis in order to pro-
vide herb safety recommendations in the context of
traditional medicine use in West Africa. Alcohol use was
not associated with liver fibrosis in our report. The role
of alcohol use in the development of liver fibrosis has
been extensively demonstrated in high-income settings.
The assessment of alcohol exposure through the AUDIT
score did not capture the lifetime exposure to alcohol
use which might be more relevant as liver fibrosis is a
relatively long process. After adjusting for all important
confounders, a fraction of the observed geographical
variation in the prevalence of liver fibrosis remains un-
explained. Unmeasured exposures to environmental risk
factors could have played a role. For example, aflatoxin
exposure which has been already linked to liver fibrosis
might not be equally distributed throughout West Africa
[45]. Additional investigations should explore the role of
environmental factors in the occurrence of liver fibrosis
and ultimately cirrhosis.
Our study population might not be representative of
all prisons in these two countries as we only focused on
selected civil prisons from the two main urban areas in
Togo and Senegal. Indeed, the diversity of prison facilities
needs to be addressed as wide variations in the prevalence
of viral hepatitis infections have been reported elsewhere.
Aside tobacco use, other addictive behaviors were pro-
hibited in these prison facilities. This might have under-
estimated the self-reported use of drugs and alcohol.
Although transient elastography is a technique rapidly
mastered and easy to reproduce, it remains an operator-
dependent procedure. An inadequate use of the device
can lead to the overestimation of LSM. In order to provide
better estimates of the burden of liver disease, larger
studies with standardized procedures are needed through-
out the African continent. In its latest guideline for the
prevention, care and treatment of HBV infection, the
WHO underlined to need to use inexpensive non-invasive
approaches to assess the extent of liver fibrosis in re-
source-limited settings. However, they also recommend to
use alternative approaches such as transient elastography
wherever available. Although being initially expensive, the
cost of transient elastography compared to alternative
non-invasive biological tests for the evaluation of liver fi-
brosis remains to be assessed in the long term. Finally, the
cross-sectional nature of the study limits our ability to
draw any causal relation between liver fibrosis and associ-
ated factors. Nevertheless, several factors including HIV
infection or the use of herbal medicines have been previ-
ously incriminated in previous cross-sectional studies. A
longitudinal assessment of the impact of these factors on
liver fibrosis will ultimately be needed.
Conclusion
Infection with HIV and HBV were high in inmates incar-
cerated in the state prisons of Lome and Dakar. Although
being relatively infrequent, severe liver fibrosis was clearly
and independently associated with both chronic hepatitis
infections and HIV infection. In a context of increasing
availability of efficient antiviral therapies for HIV and
chronic hepatitis infections, appropriate monitoring strat-
egies for liver disease need to be explored in vulnerable
populations, including prison inmates. The association be-
tween traditional medicine use and liver fibrosis highlights
the need to provide better documentation of etiologic fac-
tors leading to liver damages in sub-Saharan Africa.
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